AbCellera Biologics Inc. Increase (Decrease) in Income Taxes Payable
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Income Taxes Payable of -$4.97 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-05-11
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was -$4.97M.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was -$10.05M, a 165.44% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was -$12.20M.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for the quarter ending 2025-06-30 was -$3.18M.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for fiscal 2025 was -$29.84M, a 548.70% decline from fiscal 2024.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for fiscal 2024 was $6.65M, a 78.17% decline from fiscal 2023.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for fiscal 2023 was $30.46M.
- AbCellera Biologics Inc. increase (decrease) in income taxes payable for fiscal 2022 was -$88.61M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$4.97M 10-Q · filed 2026-05-11 | -$15.02M derived: sum of 2 quarters · filed 2026-05-11 | -$27.23M derived: sum of 3 quarters · filed 2026-05-11 | -$30.41M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | -$10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$22.25M derived: sum of 2 quarters · filed 2026-02-24 | -$25.43M derived: sum of 3 quarters · filed 2026-02-24 | -$29.84M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$12.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$15.38M derived: sum of 2 quarters · filed 2025-11-06 | -$19.79M 10-Q · filed 2025-11-06 | -$4.43M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-06-30 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$7.59M 10-Q · filed 2025-08-07 | $7.77M derived: sum of 3 quarters · filed 2026-05-11 | $5.02M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-03-31 | -$4.41M 10-Q · filed 2026-05-11 | $10.95M derived: sum of 2 quarters · filed 2026-05-11 | $8.20M derived: sum of 3 quarters · filed 2026-05-11 | $5.42M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $15.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $12.60M derived: sum of 2 quarters · filed 2026-02-24 | $9.83M derived: sum of 3 quarters · filed 2026-02-24 | $6.65M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.53M derived: sum of 2 quarters · filed 2025-11-06 | -$8.71M 10-Q · filed 2025-11-06 | -$6.93M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$5.95M 10-Q · filed 2025-08-07 | -$4.17M derived: sum of 3 quarters · filed 2026-02-24 | $1.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$3.18M 10-Q · filed 2025-05-08 | -$1.40M derived: sum of 2 quarters · filed 2026-02-24 | $4.40M derived: sum of 3 quarters · filed 2026-02-24 | $39.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.58M derived: sum of 2 quarters · filed 2026-02-24 | $43.08M derived: sum of 3 quarters · filed 2026-02-24 | $30.46M 10-K · filed 2026-02-24 |
| 2023-09-30 | $5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $41.30M derived: sum of 2 quarters · filed 2024-11-04 | $28.68M 10-Q · filed 2024-11-04 | -$24.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $35.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $22.88M 10-Q · filed 2024-08-06 | -$30.79M derived: sum of 3 quarters · filed 2025-02-27 | -$117.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$12.61M 10-Q · filed 2024-05-07 | -$66.29M derived: sum of 2 quarters · filed 2025-02-27 | -$153.47M derived: sum of 3 quarters · filed 2025-02-27 | -$171.19M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$53.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$140.86M derived: sum of 2 quarters · filed 2025-02-27 | -$158.57M derived: sum of 3 quarters · filed 2025-02-27 | -$88.61M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$87.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$104.90M derived: sum of 2 quarters · filed 2023-11-02 | -$34.93M 10-Q · filed 2023-11-02 | -$18.90M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$17.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $52.25M 10-Q · filed 2023-08-03 | $68.28M derived: sum of 3 quarters · filed 2024-02-20 | $69.05M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $69.97M 10-Q · filed 2023-05-04 | $86.00M derived: sum of 2 quarters · filed 2024-02-20 | $86.77M derived: sum of 3 quarters · filed 2024-02-20 | $62.56M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $16.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $16.80M derived: sum of 2 quarters · filed 2024-02-20 | -$7.41M derived: sum of 3 quarters · filed 2024-02-20 | -$13.53M 10-K · filed 2024-02-20 |
| 2021-09-30 | $767.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$23.44M derived: sum of 2 quarters · filed 2022-11-08 | -$29.56M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$24.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$30.33M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$6.12M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $36.41M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |